Related Experiment Video
Updated: Jun 13, 2025
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal Denervation: Patient Selection and When to Refer
Raven A Voora1, Michael J Bloch2, Naomi Dl Fisher3
1Department of Medicine, Division of Nephrology and Hypertension, University of North Carolina, Chapel Hill, North Carolina.
Abstract:
The US FDA approved Renal Denervation for hypertension treatment in November 2023. Regardless of the methodology used to denervate, most but not all people had a clinically significant reduction in blood pressure in the months following the procedure. In this review we summarize the current data informing patient selection, and provide guidance on when to refer potential patients for consideration of this therapy in the management of uncontrolled hypertension.
More Related Videos
06:30Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
Published on: September 11, 2018
03:26Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...